AKC Canine Health Foundation Funds Groundbreaking Study to Evaluate Potential Treatment for Degenerative Myelopathy
Retrieved on:
Thursday, June 1, 2023
DSM-IV codes, Tufts University, Ohio State University, Human, University, DM, Principal investigator, University of Missouri, Quality of life, Data collection, Research, North Carolina State University, Canine degenerative myelopathy, Synthetic control method, Dog, Riluzole, Spondylosis, Health, FDA, CHF, ALS, Disease, Pharmaceutical industry
RALEIGH, N.C., June 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, announces funding for a groundbreaking study evaluating a potential treatment for canine degenerative myelopathy.
Key Points:
- RALEIGH, N.C., June 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, announces funding for a groundbreaking study evaluating a potential treatment for canine degenerative myelopathy.
- Degenerative myelopathy (DM) is a progressive neurologic disease in dogs with characteristics similar to some forms of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) in humans.
- There is currently no treatment available to slow disease progression in dogs.
- The DM treatment study is part of CHF's $13.4 million active research portfolio funding studies into all aspects of canine physical and behavioral health.